PTGER2
Prostaglandin E2 receptor EP2 subtype
As of the edition of 20 October 2026, PTGER2 (prostaglandin E2 receptor EP2 subtype, UniProt P43116) has 8 drugs tested at it and 10 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43116
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Eye; Urinary and reproductive; Heart and blood vessels; Pregnancy and women's health; Nutrition and metabolism; Hormones; Cancer; Inherited and neonatal
- Registered trials of its drugs
- 93
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Went quiet | 4 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dinoprostone | Marketed | Phase 4 | none listed |
| Alprostadil | Marketed | Phase 4 | none listed |
| Omidenepag isopropyl | Marketed | Phase 4 | Ends 2035 |
| Simenepag isopropyl | Went quiet | Phase 2 | none listed |
| Taprenepag isopropyl | Went quiet | Phase 2 | none listed |
| Evatanepag | Went quiet | Phase 2 | none listed |
| PF-04418948 | Went quiet | Phase 1 | none listed |
| Diclofenac etalhyaluronate | Marketed | No phase stated | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Undetermined | 7 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Santen Pharmaceutical | Route B |
| AbbVie | Route A |
The other 7 companies at PTGER2
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at PTGER2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.